Reported 1 day ago
Gilead Sciences (GILD) reached an all-time high after announcing strong earnings for the second quarter, showcasing a 22.5% increase in net income. Ten analysts upgraded their ratings for the stock, boosting price targets significantly, with Morgan Stanley raising theirs to $143. Gilead also revised its annual product sales growth forecast upward, reflecting positive market sentiment.
Source: YAHOO